Does pharmacokinetic variability influence the efficacy of high-dose methotrexate for the treatment of children with acute lymphoblastic leukemia: What can we learn from small studies?
- 1 May 1997
- journal article
- editorial
- Published by Elsevier in Leukemia Research
- Vol. 21 (5) , 435-437
- https://doi.org/10.1016/s0145-2126(96)00128-2
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- On the prognostic value of systemic methotrexate clearance in childhood acute lymphocytic leukemiaLeukemia Research, 1997
- Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia.Journal of Clinical Investigation, 1994
- Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study.Journal of Clinical Oncology, 1994
- Statistical aspects of prognostic factor studies in oncologyBritish Journal of Cancer, 1994
- The influence of serum methotrexate concentrations and drug dosage on outcome in childhood acute lymphoblastic leukaemiaBritish Journal of Cancer, 1991
- Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysisBlood, 1990
- MTX clearance is more important for intermediate-risk ALL.Journal of Clinical Oncology, 1990
- Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearanceClinical Pharmacology & Therapeutics, 1986
- Clinical Pharmacodynamics of High-Dose Methotrexate in Acute Lymphocytic LeukemiaNew England Journal of Medicine, 1986
- METHOTREXATE SYSTEMIC CLEARANCE INFLUENCES PROBABILITY OF RELAPSE IN CHILDREN WITH STANDARD-RISK ACUTE LYMPHOCYTIC LEUKAEMIAThe Lancet, 1984